LINK:  https://bswhealth.webex.com/bswhealth/j.php?MTID=m872d4aebf3b2566962f7e237323c2485

OBJECTIVES: Upon completion of this activity, the participant should be able to:  (1) Describe mechanism of action of Ileal bile acid transporter (IBAT) inhibition. (2) Review evidence from clinical trials of IBAT inhibitors in cholestatic liver disorders. (3) Discuss safety, tolerability, and potential benefits of IBAT inhibitors.

FACULTY DISCLOSURE: Nadia Ovchinsky, MD, MBA was a consultant for Albireo Biotech and Mirum Pharmaceutical Companies.

PLANNER DISCLOSURE: James Trotter, MD, Sumeet Asrani, MD, Gregory McKenna, MD, and Kathy Brown, RN, CCTC, have no relevant financial relationship(s) to disclose with companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships have been mitigated.

ACCREDITATION: The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

DESIGNATION:  The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CEPTC Credit: The American Board for Transplant Certification (ABTC) has been applied for educational offering for up to 1 Category 1 Continuing Education Point for Transplant Certification (CEPTCs).

For information, please contact Karina Pena at [email protected]